*Curriculum Vitae*

**HENRY M. BLUMBERG, M.D.**

***OFFICE ADDRESS/PHONE:*** Division of Infectious Diseases

 Department of Medicine

 Emory University School of Medicine

 49 Jesse Hill Jr Drive

 Atlanta, Georgia 30303

 (404) 727-5096

 (404) 880-9305 (fax)

***E-MAIL ADDRESS:*** henry.m.blumberg@emory.edu

***DATE OF BIRTH:***July 21, 1957 in Philadelphia, PA

***CITIZENSHIP*** USA

***CURRENT TITLES/AFFLIATIONS/FACULTY APPOINTMENTS:***

 Professor of Medicine (with tenure) 9/2003-present

 Division of Infectious Diseases

 Emory University School of Medicine

 Professor of Epidemiology 9/2003-present

 Emory Rollins School of Public Health

 Professor of Global Health 10/2010-present

 Hubert Department of Global Health

 Emory Rollins School of Public Health

 Director, Clinical and Translational 9/2007-present

 Research Training Programs

 Atlanta Clinical and Translational Science Institute (ACTSI, NIH funded CTSA)

 Woodruff Health Sciences Center

 Emory University

 Investigator and Member 9/2014-present

 Emory Vaccine Center

 Co-Program Director 7/2012-present

 Emory Global Health Residency Scholars Program

 Emory University School of Medicine

 Chair, Infection Control Committee 1999-present

 Grady Memorial Hospital

 Atlanta, Georgia

***PREVIOUS ACADEMIC AND***

***PROFESSIONAL APPOINTMENTS:***

 Co-Course Director 2010-2014

 Discovery Phase, Emory Medical Student Curriculum

 Hospital Epidemiologist 2/1992-6/2010

 Grady Memorial Hospital

 Program Director

 Division of Infectious Diseases 5/2000-6/2008

 Emory University School of Medicine

 PI/Program Director 10/2002-9/2007

 Emory Mentored Clinical Research Scholars Program

 (NIH Funded K12 Program)

PI/Program Director 6/2006-9/2007

Clinical Research Curriculum Award/

 Master of Science in Clinical Research Program

(CRCA/MSCR NIH funded K30 Program)

 Both the K12 and K30 programs were incorporated into the

 ACTSI, the NIH-funded CTSA in September 2007)

 Associate Professor of Medicine 9/97-8/2003

 (with Tenure) tenure received 2000

 Division of Infectious Diseases

 Emory University School of Medicine

 Assistant Professor of Medicine 2/92-8/97

 Division of Infectious Diseases

 Emory University School of Medicine

 Associate in Medicine 7/86-6/87

 Emory University School of Medicine

 and

 Staff Physician

 Infectious Diseases/AIDS Clinic

 Grady Memorial Hospital

 Associate Professor of Epidemiology 9/2000-8/2003

 Rollins School of Public Health

 Emory University

 Associate Director 12/2003-6/2006

Clinical Research Curriculum Award

(CRCA/MSCR NIH funded K30 Program

***MEDICAL LICENSURE:*** State of Georgia #027160 1984-present

DEA # AB3124473 (Expiration Date 7/2017)

***BOARD CERTIFICATION:*** Board Certified, Infectious Diseases 1990, 2000, 2010

 Board Certified, Internal Medicine 1986

 American Board of Internal Medicine

 Diplomate 1984

 National Board of Medical Examiners

***EDUCATION:*** Washington University 8/75-5/79

 St. Louis, MO

 B.A., *cum laude,* 1979

 Biology/Political Science

 Vanderbilt University 8/79-5/83

 School of Medicine M.D., 1983

 Nashville, TN

***POSTGRADUATE TRAINING:*** Department of Medicine 7/1983-6/1986

***Residency*** Emory University Affiliated Hospitals Program

 Atlanta, Georgia

 Supervisor-J. Willis Hurst, M.D.

 Chief Resident in Medicine 7/1987-6/1988

 Crawford Long Hospital of Emory University

[now Emory University Hospital Midtown]

Supervisor-Jonas A. Shulman, M.D.

***Fellowship Training*** Infectious Diseases Fellow 7/1988-1/1992

 Division of Infectious Diseases

 Department of Medicine

 Emory University School of Medicine

 Supervisor-W. Lee Hand, M.D.

 Guest Scientist 7/1989-6/1992

 Centers for Disease Control

 And Prevention (CDC)

 Atlanta, Georgia

Supervisor-I. Kaye Wachsmuth, Ph.D.

***COMMITTEE MEMBERSHIPS:***

**National and International** Tuberculosis Transformative 2011-present

 Science Group (TSG)

 NIH AIDS Clinical Trials Group (ACTG)

 Infectious Diseases Society of America 2008-present

 (IDSA) Global Center Scientific

 Advisory Committee

 Workforce Development Domain Task Force 2015-present

 NIH National Center for Advancing Translational Research

 (NIH NCATS)

 TB Interest Group Steering 2005-present

 Committee, IDSA

 Tuberculosis Committee 1998-2002

 (IDSA)

 Chair, IDSA TB Committee 11/1999-10/2002

 Chair, Nominations Committee 2003-2004

 Society for Healthcare Epidemiology

 of America (SHEA)

 SHEA Liaison to CDC National 2009-2011

 Healthcare Safety Network (NHSN)

 Steering Committee Work Group

 SHEA Nominations Committee 2003-2005

 2007

 SHEA Patient Safety and Quality 2009

 Improvement Committee

 Colorado Clinical and Translational 2010-2011

 Science Institute

 External Advisory Committee

 Publications and Presentations Committee 2007-2011

 TB Epidemiologic Studies Consortium

 CDC

Research Advisory Committee 2002-2005

 TB Epidemiologic Studies Consortium

 CDC

 STOP-TB/WHO 2007-present

 TB Infection Control Subgroup

NIH CTSA Education/ 2007-2013

 Career Development Committee

 External Advisory Committee of the 2008-2012

 National CTSA Educational Resource Program

CFAR HIV/TB Working Group 2009-2012

 Co-Chair 2001-2005

 Control of Tuberculosis in the U.S.

 Statement Revision –ATS/CDC/IDSA

 Co-Chair 1999-2003

 Treatment of Tuberculosis Statement

 American Thoracic Society (ATS)/

 Centers for Disease Control and Prevention (CDC)/

 Infectious Diseases Society of America (IDSA)

 Committee on Occupational Health 1997-2003

 (formerly TB/AIDS Committee)

 Society for Healthcare Epidemiology

 of America (SHEA)

 Institute of Medicine 2000-2001

 Committee on Regulating Occupational

 Exposure to Tuberculosis

 "Tuberculosis in the Workplace"

**Regional and State** Metro Atlanta TB Task Force 1993-present

 Advisor, Georgia Medical Care 1998-2005

 Foundation/Georgia Hospital Association

 CQIP Plus Surgical Prophylactic

 Antibiotic Project

 State of Georgia, Vancomycin 1997-2003

 Resistant *Enterococcus* (VRE) State Task Force

**Grady Health System** Infection Control Committee 1992-present

 Co-Chair, Infection Control Committee 1995-1998

 Chair, Infection Control Committee 1999-present

 Grady Memorial Hospital

 Anti-Infectives Subcommittee 1993-present

 Grady Memorial Hospital

 Pharmacy and Therapeutics Committee 1998-present

 Grady Memorial Hospital

 Medical Errors/Safety Committee 2001-2009

 Grady Health System

**Emory University** Director, Research Education, Training 2007-Present

 and Career Development Program (RETCD)

 Atlanta Clinical and Translational Science

 Institute (NIH-funded Clinical and Translational Science

 Award [CTSA])

 Masters of Science in Clinical Research Program

 Executive Committee 1998-present

 Woodruff Health Sciences Center

 Member--Admissions Committee 2000-Present

 Emory University School of Medicine

 Associate Member—Admissions 1997-2000

 Committee

 Emory University School of Medicine

 Medical Student Discovery Phase 2009-2014

 Co-Course Director

 Emory Medical Care Foundation 1999-2013

 Research Committee

***MANUSCRIPT REVIEWER:*** Ad hoc reviewer: 1994-Present

 *New England Journal of Medicine*

 *Lancet*

 *Journal of the American Medical Association (JAMA)*

 *Annals of Internal Medicine*

 *Annals of Epidemiology*

 *American Journal of Respiratory and Critical Care Medicine*

 *Clinical Infectious Diseases*

 *Journal of Infectious Diseases*

 *American Journal of Epidemiology*

 *Emerging Infectious Diseases*

 *Infection Control and Hospital Epidemiology*

 *International Journal of Tuberculosis and Lung Disease*

 *American Journal of Medical Sciences*

 *PLoS ONE*

***HONORS AND AWARDS:*** Phi Beta Kappa, Washington University 1979

 St. Louis, MO

 Sigma Xi, Washington University 1979

 NIH TB Academic Award 1993-2006

 Grady Great 100 Top Physician Award 2000

 *Atlanta* Magazine’s “Top Doctors” 2001, 2005, 2011

 Dean’s Teaching Award, Emory 2002-2003

 University School of Medicine

 Fellow, American College of Physicians 2003-Present

 Fellow, Infectious Diseases Society 2003-Present

of America (IDSA)

 Fellow, SHEA 2003-Present

 America’s Top Doctors, Castle Connolly 2003, 2004, 2005

 2007-2013

 Paul Beeson Faculty in Infectious 2008

 Diseases Recognition Award

 Georgian National TB Program 2010

 Outstanding Support Award

 Department of Medicine Shanthi V. Sitaraman

 Silver Pear Mentoring Award 2013

 Emory University School of Medicine

 Marion V. Creekmore 2014

 Internationalization Award

 Emory University

***SOCIETY MEMBERSHIPS:*** Infectious Diseases Society of America (IDSA)

 Society for Healthcare Epidemiology of America (SHEA)

 American College of Physicians

 Southern Society for Clinical Investigation

 American Federation for Medical Research

 International AIDS Society

 International Union Against Tuberculosis and Lung

 Disease (IUATLD)

 Association of Subspecialty Professors (ASP)

 Consortium of Universities for Global Health (CUGH)

***ORGANIZATION OF NATIONAL OR***

 ***INTERNATIONAL CONFERENCES***

 US-Georgia Workshop June 2015

 Emory-Georgia TB Research Training Program

 “Fogarty Trainee and Alumni Research Workshop: Career

 Development and Building TB-related Research Capacity

 Kazbegi, Georgia

 Ethiopia-Emory TB Research Training July 2015

 Program: “Fogarty Trainee Research Workshop:

 Development and Building TB-related Research Capacity

 Bishoftu, Ethiopia

 Translational Science 2014 April 2014, 2015

 TL1 Component Steering Committee

 US-Georgia Workshop June 2012

 Infectious Disease Research Conference:

 “Fogarty Trainee and Alumni Research Workshop: Career

 Development and Building Infectious Diseases Research

 Capacity

 Tbilisi, Georgia

 2011 Clinical and Translational April 2011

 Research and Education Meeting

 ACRT/SCTS/AFMR Joint Annual Meeting

 Member, Annual Meeting Program Committee

 US-Georgia Workshop July 2010

 Infectious Disease Research Conference:

 “Building Human Capacity for Research in HIV, TB,

 and Hepatitis”

 Tbilisi, Georgia

 US-Georgia Workshop May 2009

 Infectious Disease Research Conference:

 “Implementation Science and Strengthening In-Country

 Partnerships”

 Tbilisi, Georgia

 US-Georgia Workshop: The May 2008

 Intersections of TB, HIV, Hepatitis and

 Substance Abuse in Georgia. Setting the

 Research Agenda in Infectious Diseases

 Tbilisi, Republic of Georgia May 2008

***ORGANIZATION OF NATIONAL OR***

 ***INTERNATIONAL CONFERENCES***

(*continued*)

TB-HIV Workshop for South November 2006

 Caucasus Countries

 Tbilisi, Republic of Georgia

 U.S.-Caucasus Workshop on October 2005

 Operational Research in HIV, TB and

 Infectious Diseases

 Tbilisi, Republic of Georgia

 Chair and Moderator October 2002

 Tuberculosis Workshop

 IDSA Annual Meeting

 Chair and Moderator October 2001

 Tuberculosis Workshop

 IDSA Annual Meeting

 Chair and Moderator September 2000

 Tuberculosis Workshop

 IDSA Annual Meeting

 Tuberculosis Infection Control December 1999

 in the 21st Century

 (Co-sponsored by the ATS, IDSA)

 Organizing Committee Member

 Moderator for two sessions:

 "Current Institutional Infection Control Practices"

 and "The contribution of community transmission"

***RESEARCH FOCUS:*** Tuberculosis and Global Health

 Healthcare and Molecular Epidemiology

 Clinical and Translational Research Training

Research and other Academic Interests:

My research and academic interests are particularly focused on tuberculosis, global health, and clinical/translational research training (both in the U.S. and internationally). I also have an interest in healthcare epidemiology. TB and TB/HIV-related research activities are focused on clinical and translational research activities that include: transmission dynamics of *Mycobacterium tuberculosis*, multidrug resistant (MDR) and extensively drug resistant TB; molecular diagnostics; TB/non-communicable disease interactions; TB-related immunology (specifically the role of antigen-specific T cell responses in the control of TB which is the focus of our NIH NIAID Tuberculosis Research Unit [TBRU] grant for which I serve as dual PI); and implementation science. Global Health activities are particularly focused on tuberculosis (in Kenya, the country of Georgia, and Ethiopia) as well as clinical and translational research training in the countries of Georgia and Ethiopia.

***GRANT SUPPORT:***

***Active Research Support***

 ***Federal:***

 U19 AI111211 National Institutes of Health

 National Institute of Allergy and Infectious Diseases

 08/11/2014 - 7/31/2021 ($18.7 million; 2,704,904 in year 1)

 Tuberculosis Research Unit (TBRU): Role of antigen-

 specific T-cell responses in the control of TB

 dual Principal Investigators: Henry M. Blumberg, M.D. and

 Joel Ernst, M.D.

 D43 TW009127 National Institutes of Health

 Fogarty International Center (FIC)

 2013-2018 ($194,093 per year)

 Ethiopia-Emory TB Research Training Program

 Principal Investigator: Henry M. Blumberg, M.D.

 D43 TW007124 National Institutes of Health

 Fogarty International Center (FIC)

 Emory-Georgia Tuberculosis Research Training Program

 2004-2019 ($250,000 per year)

 Principal Investigator: Henry M. Blumberg, M.D.

 Contract 200-2011-41278

 Centers for Disease Control and Prevention (CDC)

 Tuberculosis Epidemiologic Studies Consortium (TBESC); 2011-2021 $4,790,249 over 10 years

 Principal Investigator: Henry M. Blumberg, M.D

***GRANT SUPPORT:***

***Active Research Support***

 (*continued*)

 UL1TR000454, KL2TR000455, TL1TR000456

 9/17/2007-5/31/2017 ($31 million 2012-2017)

 National Institutes of Health/NCATS

 Atlanta Clinical and Translational Science Institute

 (NIH Clinical and Translational Science Award [CTSA])

 Principal Investigator: David Stephens, M.D.

 Program Director, Research Education, Training and

 Career Development (RETCD): Henry M. Blumberg, M.D.

 Office of the U.S. Global AIDS Coordinator (OGAC)/NIH/HRSA

 Medical Education Partnership Initiative (MEPI): Ethiopia's

 Medical Education Consortium for Quality Medical Education & Retention. 9/2010-8/2015 ($2 million/year)

 PI: Miliard Derbew, M.D. [Addis Ababa University]

 PI of Emory subcontract: Henry M. Blumberg, M.D

  ***State:*** Georgia Department of Public Health

 Contract PH-10100210-88

 Control of Multiple Drug-Resistant Tuberculosis

 8/1993-12/2015 ($1,279,840) ($53,00 annually)

 Principal Investigator: Henry M. Blumberg, M.D.

***Previous Research Support:***

 Howard Hughes Medical Institute--Med into Grad Initiative

 Atlanta Clinical and Translational Science Institute (ACTSI)

 Med into Grad Initiative: Translational and Transformative

 Research Training

 3/2010-6/2015 $700,000

 Principal Investigator: Henry M. Blumberg, M.D.

University of Georgia (FDA grant)

Development of a Diagnostic Test for Latent Tuberculosis Infection

 11/2012-8/2014 ($87,871)

 [no cost extension through 2/28/2015]

 PI of Emory subcontract: Henry M. Blumberg, M.D.

 Global Health Institute of Emory University

 Risk Factors for Tuberculosis among HIV-Infected Patients

 in Ethiopia and Strategies for Enhancing Case Finding

 2011- 2014 $50,000

 Principal Investigator: Henry M. Blumberg, M.D.

 Global Health Institute of Emory University

 Prevalence and Risk Factors for Extensively Drug Resistant

 TB (XDR-TB): A Population Based Study in Georgia

 2011-12/2014 ($20,000)

 Principal investigator: Russell Kempker, MD, MSC

 co-PI: Henry M. Blumberg, M.D.

 Global Health Institute of Emory University

 Impact of Vitamin D Supplementation on Host

 Immunity to *Mycobacterium tuberculosis* and Response

 to Treatment: Building Translational Research Capacity

 in Nutrition and Infectious Diseases in the Republic of

 Georgia

 9/2008-12/2012 ($250,000)

 Principal Investigator: Thomas Ziegler, M.D.

 co-PI: Henry M. Blumberg, M.D.

 University of Michigan-Bill and Melinda Gates Foundation

 Landscaping Grant: Emory—Addis Ababa University

 (AAU) Academic Health Center Partnership Program 1/2010-1/2013 ($100,000)

 Principal Investigator: Henry M. Blumberg, M.D.

***Previous Research Support:*** D43TW007124-06S109 NIH/FIC ARRA supplement

*(continued)* GEB2-2935-TB-08

 U.S. Civilian Research and Development

 Foundation (CRDF)

 Risk Factors for Extensively Drug Resistant Tuberculosis

 and Evaluation of the GenoType MTBDRplus Assay for

 Rifampin and Isoniazid Rapid Susceptibility Testing in

 Country of Georgia

 6/2009 - 11/2011 $90,000

 Principal Investigator: Henry M. Blumberg, M.D.

 2009-2011 ($172,186)

 Emory-Georgia Tuberculosis Research Training Program--

 Fogarty ARRA Supplement for U.S. Global Health

 Postdoctoral Scientist.

 principal Investigator: Henry M. Blumberg, M.D.

 Centers for Disease Control and Prevention (CDC)

 200-2001-00086

 Tuberculosis Epidemiological Studies Consortium (TBESC)

 2001-2011 ($4,000,000)

 projects included:

“Prospective Evaluation of Risk Factors for transmission of

 *M. tuberculosis* from case-patients to contacts”

 “Prospective evaluation of immunogenetic susceptibility to

 *M. tuberculosis* infection and surrogate markers for

 tuberculosis infection and disease”

 “Prevalence of Latent Tuberculosis Infection among High

 Risk Populations in the U.S. and Canada”

“A National Genotyping Registry for a Molecular Epidemiological Analysis of Multidrug-Resistant Tuberculosis, USA and Canada”

 “Enhanced surveillance to identify missed opportunities for

 TB prevention in foreign-born populations in the United

 States and Canada”.

 “National Study of Determinants of Early Diagnosis,

 Prevention, and Treatment of TB in the African-American

 Community”

 “Improving the Utilization and Integration of Genotyping”

 “TB Mortality in the United States: Epidemiology and

 Prevention Opportunities”

 “Use of Nucleic Acid Amplification Test to Determine the

 Relative Infectiousness of Pulmonary TB Patients”

 Principal Investigator: Henry M. Blumberg, M.D.

***Previous Research Support:***

*(continued)*

 U01DK069322I National Institutes of Health

 NIDDK

 Efficacy and Mechanisms of GLN Dipeptide in the SICU

 2005-2010 $501,831/year

 principal investigator: Thomas Ziegler, M.D.

 Role: Co-Investigator

 Global Health Institute of Emory University

 Zambia-Emory Research Initiative in Tuberculosis and

 TB/HIV 9/2007-12/2010 ($161,198)

 Principal Investigator: Henry M. Blumberg, M.D.

 U.S. Civilian Research and Development Foundation

 (CRDF) GEX1-2725-TB-07

 Role of Hepatitis C Virus (HCV) as a Risk Factor for

 Antituberculosis Drug-induced Hepatotoxicity

 4/2007-6/2010 ($100,000)

 U.S. Principal Investigator: Henry M. Blumberg, M.D.

 Georgian principal investigator: Lali Kupreishvili, M.D.

K12 RR017643 National Institutes of Health

 Division of Clinical Research

 National Center for Research Resources

 Emory Mentored Clinical Research Scholar Program

 2002-2007 ($5,100,000)

 Principal Investigator: Henry M. Blumberg, M.D.

 [incorporated into the NIH CTSA Award]

K30RR022291

 National Institutes of Health/NCRR

 Clinical Research Curriculum Award

 6/2005-9/2007 ($300,000/year)

 Principal Investigator: Henry M. Blumberg, M.D.

 [incorporated into the NIH CTSA Award]

 Bacterial and Mycoses Study Group (BAMSG)

 NIH/UAB—4-01 Study

 Strategies to Reduce Transmission of Antimicrobial

 Resistant Organisms

 2/2005-4/2007 ($156,000)

 PI: Henry M. Blumberg, M.D.

***Previous Research Support:***

*(continued)*

 T01/CCT424389

 Centers for Disease Control and Prevention (CDC)

 Postdoctoral Fellowship Training Program in Infectious

 Diseases

 9/20/04-8/2007 ~$184,367

 Principal Investigator: Henry M. Blumberg, M.D.

 CDC Foundation

 Sharps Safety Program

 2005-2007 $100,000

 Principal Investigator: Henry M. Blumberg, M.D.

 CDC Foundation

 Prevalence of Latent Tuberculosis Infection among High

 Risk Populations: HIV-Infected Patients

 2005-2007 $29,000

 Principal Investigator: Henry M. Blumberg, M.D

 K07 HL03078 National Institutes of Health

 National Heart, Lung and Blood Institute (NHLBI)

 TB Academic Award/Emory Tuberculosis Education and

 Control Program

 1993-2006 ($783,157).

 Includes supplements for TB Academic Award Minority

Medical School Partnership Program; Clinical and

Molecular Epidemiology of Drug Resistant Tuberculosis in the Republic of Georgia

 Principal Investigator: Henry M. Blumberg, M.D.

 U.S. Civilian Research and Development Foundation

 Clinical and Molecular Epidemiology of Drug Resistant

 Tuberculosis in the Republic of Georgia

 7/00-11/02 ($57,000)

 principal U.S. investigator: Henry M. Blumberg, M.D.

 Pfizer, Inc.;

 Epidemiology of *Candida* Bloodstream Infections: A Multicenter Study (NEMIS Study).

 1993-2002 ($1,255,202)

 Principal Investigator: Henry M. Blumberg, M.D.

***Previous Research Support:***

*(continued)* Emory Medical Care Foundation General Fund

 "Establishment of an Epidemiology Investigation

 Laboratory to Support Infection Control Activities at

 Grady Memorial Hospital"; $91,000.00

 1993-2006

 Principal Investigator: Henry M. Blumberg, M.D.

 CDC/VA Foundation

 “Infections among HIV-seropositive patients in the home

 care setting”

 10/98-12/01 ($179,536)

 co-investigator: Henry M. Blumberg, M.D.

 American Lung Association of Georgia

 Atlanta Tuberculosis Prevention Coalition

 7/97-8/01 ($301,000)

 Principal Investigator: Henry M. Blumberg, M.D.

 Emory Medical Care Foundation Research Fund

 “Expanding preventive therapy for tuberculosis infection: a

 randomized trial of short course (2 months rifampin and

 pyrazinamide) vs. standard (6 months INH) preventive ”.

 10/99-11/2001 ($25,000)

 Principal Investigator: Henry M. Blumberg, M.D.

 Centers for Disease Control and Prevention (CDC)

 Evaluation of tuberculin skin test positive health care workers

 11/99-11/2000 ($13,000)

 Principal Investigator: Henry M. Blumberg, M.D.

 Bristol-Myers Squibb

 Amphotericin B Oral Suspension vs. Amphotericin B/

 Optimoist Oral Moisturizer for the Treatment of

 Oropharyngeal Candidiasis in HIV/AIDS Patients.

 5/98-12/00 ($142,163)

 Principal Investigator: Henry M. Blumberg, M.D.

 U.S. Civilian Research and Development Foundation

 (CRDF)

 Clinical and Molecular Epidemiology of Tuberculosis in

 the Republic of Georgia. 10/97-3/00 ($35,000)

 principal U.S. investigator: Henry M. Blumberg, M.D.

***Previous Research Support:***

*(continued)*

 Robert Wood Johnson Foundation

 TB Demonstration Project

 "Atlanta Tuberculosis Project and TB Prevention Coalition"

 1994-1997 ($1,155,000)

 Principal Investigator: Henry M. Blumberg, M.D.

 Pfizer, Inc.;

 “Prospective Study of Oropharyngeal Candidiasis in AIDS

 Patients: Clinical and Molecular Epidemiology”

 9/96-12/98 ($375,000)

 Principal Investigator: Henry M. Blumberg, M.D.

 University Research Council of Emory University

 Clinical and Molecular Epidemiology of Tuberculosis in

 the Republic of Georgia 9/97-8/98 ($15,000)

 Principal Investigator: Henry M. Blumberg, M.D.

 Emory Medical Care Foundation Research Fund

 "Molecular Epidemiology of Group B Streptococcal

 Infections"; $30,000.00 (6/92-5/93).

 Principal Investigator: Henry M. Blumberg, M.D.

 Georgia Department of Human Resources

 Contract Number 427-93-31741; “Control of Tuberculosis,

 including multidrug resistant TB”, $62,139.00 (10/92).

 Principal Investigator: Henry M. Blumberg, M.D.

 University Research Committee, Emory University

 "Molecular Epidemiologic Investigation of Group B

 Streptococcal Infections", $10,000 (9/93-8/94).

 Principal Investigator: Henry M. Blumberg, M.D.

***CLINICAL SERVICE***

***CONTRIBUTIONS:***

I attend on the Infectious Diseases Consult Service at Grady Memorial Hospital. In addition, I serve as the Chair of the Grady Infection Control Committee and previously served as Hospital Epidemiologist at Grady Memorial Hospital for 18 years. I am therefore involved in a number of areas related to healthcare epidemiology, infection control and prevention. In the role of Hospital Epidemiologist, I established the annual required Housestaff and Medical Student orientation (2nd-4th year students) sessions on infection control and tuberculosis related issues as well as a “hands-on” infection control session for Medicine PGY-1 residents and all 3rd year medical students. Establishing a comprehensive program to prevent nosocomial transmission of tuberculosis at Grady Memorial Hospital was a priority area and our efforts have been recognized nationally. We have worked closely with and have coordinated efforts with regard to TB control with local and state health departments to ensure close follow up and continuity of care once TB patients are discharged. I serve on several Grady Memorial Hospital committees including the Infection Control Committee (chair), Pharmacy and Therapeutics Committee, and the Anti-Infectives Subcommittee.

***FORMAL TEACHING:***

**Medical Students**

 Discovery Phase 2009-2014

 Co-Course Director

 Discovery Phase Mentor 2010-present

 Tuberculosis Lectures 2008-2013

 M1 New Curriculum

 Tuberculosis Lectures 1996-2006

 Microbiology of Mycobacteria

 Sophomore Microbiology Course

 Antituberculosis therapy 1996-2008

 Sophomore Pharmacology Course

 Faculty Mentor 1993-2007

 Problem Based Learning

 Emory University School of Medicine

 Preceptor 1988-2007

 Sophomore Pharmacology Course

 Emory University School of Medicine

 Coordinator for Infection Control 1992-2002

 Issues and Tuberculosis Orientation

 Sophomore, Junior and Senior Medical Students

 Emory University School of Medicine

 Department of Medicine 1997-2007

 Infection Control and Tuberculosis

 Orientation

***FORMAL TEACHING:***

**Graduate/Post-Graduate** Prevention of Nosocomial 1995-present

 Transmission of Tuberculosis

 Hospital Epidemiology Course

 Emory Rollins School of Public Health

 Lecturer and Course Co-Director 1999-present

 Research Colloquium

 Emory MSCR Program

 MSCR Lecturer 1999-present

 Introduction to Clinical and Translational

 Research

 Emory MSCR Program

 Co-Program Director 7/2012-present

 Emory Global Health Residency Scholars Program

 Emory University School of Medicine

 Tuberculosis Lecture 2/2010-present

 Emory Pulmonary Fellows Core Curriculum

 Medicine and Infectious Diseases 1991-Present

 Attending, Grady Memorial Hospital

 J. Willis Hurst Internal Medicine Residency Program

 8th Annual Resident Research Day

 Keynote talk: "Challenges and Opportunities for Physician-

 Scientists: Not a Linear Equation

 Emory University; Atlanta, GA February 2011

 Coordinator 1994-2007

 Graduate Medical Education--House

 Staff Infection Control and TB

 Orientation (15 sessions given annually

 to 1000 Emory University Affiliated

 Hospitals Housestaff)

 Department of Medicine Infection 1994-2007

 Control Orientation for New Housestaff

 Program Director, K12-Emory Mentored 2002-2007

 Clinical Research Scholars [EMCRS] Program

 Clinical Research Curriculum Award/ 1999-2007

 Masters of Science in Clinical

 Research Program

 Executive Committee

 Anesthesiology Grand Rounds 10/2012

 Emory University

 Hand Hygiene/Infection Control

 Coordinator—Journal Club 1999-2001

 Emory Division of Infectious Diseases

 Treatment of Tuberculosis 1995-2001

 Tuberculosis Course

 Rollins School of Public Health

 Infection Control Orientation 1997-2007

 Allied Health Professions

 Treatment of Tuberculosis 1995-2002

 Disease and Latent TB Infection

 HIV/TB Miniresidency

 SEATEC/Georgia DHR

 Coordinator, Research Seminar Series 1995-1998

 Division of Infectious Diseases

 Department of Medicine

Medical Grand Rounds 6/87, 4/88, 5/88

 Crawford Long Hospital 12/95, 12/2001

 Medical Grand Rounds 10/1999

 Atlanta Medical Center

Dermatology Grand Rounds 11/2001

 Emory University

 Biological Weapons

***SUPERVISORY TEACHING:***

***Post-doctoral Fellows:***

Susan Ray, M.D.

Current Position: Professor of Medicine

 (Infectious Diseases), Emory University School

 of Medicine; Hospital Epidemiologist,

 Grady Memorial Hospital

 Ben J. Barnett, M.D.

 Current Position: Associate Professor of Medicine

 (Infectious Diseases), University of Texas--Houston

 School of Medicine

 Associate Director for HIV Services and Medical Director,

 HCV-HIV co-infection clinic, Harris Health System;

 Fellowship Director, UT HIV Medicine fellowship

***SUPERVISORY TEACHING:***

***Post-doctoral Fellows:***

(*continued*) Michael K. Leonard, Jr., M.D.

 Current Position: ID Consultants, Charlotte, NC

 Previous Position: Associate Professor of Medicine

 (Infectious Diseases), Emory University School of Medicine; Tuberculosis Consultant, Georgia Division of

 Public Health

 Mark King, M.D., MSc

 Boulder, Colorado

 Previous Position: Assistant Professor of Medicine

 Division of Infectious Diseases

 Emory University School of Medicine; Director, Antibiotic

 Utilization Team, Grady Memorial Hospital

Bernard Camins, M.D., MSc

Current Position: Associate Professor of Medicine,

 Division of Infectious Diseases

 University of Alabama—Birmingham (UAB)

Hospital Epidemiologist

 UAB Hospital

Ulrich Seybold, M.D., MSc

 University of Munich

 Faculty of Medicine

 Munich, Germany

 Naasha J. Talati, M.D., MSc

 Assistant Professor of Medicine

 Division of Infectious Diseases

 University of Pennsylvania School of Medicine

 Alexandra Yamshchikov, M.D.

 Assistant Professor of Medicine

 Division of Infectious Diseases

 University of Rochester School of Medicine

 Russell Kempker, M.D., MSc

 Assistant Professor of Medicine

 Division of Infectious Diseases

 Emory University School of Medicine

 Jennifer Whitaker, M.D., MSc

 Assistant Professor of Medicine

 Division of General Medicine

 Division of Infectious Diseases

 Mayo Clinic and Mayo Medical School

 Jeffrey Collins, M.D., MPH

 Infectious Diseases Fellow

 Division of Infectious Diseases

 Emory University School of Medicine

***Thesis advisor***

***MPH/MSPH Students:*** Mark Sotir, MPH (Epidemiology) 1996

 "Gastrointestinal illness after the 1995 Emory Division of

 Infectious Diseases summer picnic: logistic regression

 modeling used in a foodborne outbreak investigation"

 Brian S. Metzger, MPH (Epidemiology) 1997

 "An examination of the possible risk factors for returning to

 have a PPD read, PPD positivity, and completing preventive

 therapy in a high risk inner-city population"

 J. David Guzman, MSPH (Epidemiology) 1999

 "Score for neonatal acute physiology as a measure of risk

 for a *Candida* bloodstream infection"

Kathleen Egan, MPH (Epidemiology) 2001

 "Risk factors for fluconazole-resistant oropharyngeal

 candidiasis"

 Christopher Lindley, MPH (Epidemiology) 2001

 "Risk factors for long term vascular access device-

 associated infections among HIV-seropositive persons"

 Isabel Hernandez Ramos, M.D., 2002

 MPH (Epidemiology)

 “Venous access device-related infections among

 HIV/AIDS patients

 Ekaterina Kourbatova, M.D., 2004

 MPH (Epidemiology)

 Risk factors for colonization with methicillin-resistant

 *S. aureus* in patients admitted to an inner-city hospital”

 Veriko Mirtskhulava, M.D. 2007

 MPH (Global Epidemiology)

 Prevalence and risk factors for latent tuberculosis

 infection among health care workers in the country of Georgia

 Nisha Nair, MPH (Epidemiology) 2008

 Prevalence and Molecular Epidemiology of Methicillin-

 Resistant *Staphylococcus aureus* (MRSA) among Patients in

 Adult Intensive Care Units: the STAR-ICU Trial

***Thesis advisor—MSCR***

 Mark King, MD, MSc 2001

 “Human Papillomavirus–associated oral warts among

 Human Immunodeficiency Virus–seropositive patients in

 the era of highly active antiretroviral therapy: an emerging

 infection”

 Bernard Camins, M.D., MSc 2005

 Population-based study of invasive vancomycin-resistant

 *Enterococcus* (VRE) in metropolitan Atlanta.

 Ulrich Seybold, M.D., MSc 2007

 Colonization with methicillin resistant *Staphylococcus*

 *aureus* (MRSA) in the High Risk Newborn Units,

 1993-2006:molecular and epidemiologic analyses

 Nino Lomtadze, M.D. ,MSc 2007

 Prevalence and risk factors for multi-drug resistant

 tuberculosis in the Republic of Georgia: a population-

 based study

 Sopio Chochua, M.D., MSc 2008

 Molecular Epidemiology of Tuberculosis

 in the Republic of Georgia

 Medea Gegia, M.D., MSc 2011

 Risk Factors for Poor Treatment Outcomes among

 Patients with Multidrug and Extensively Drug-Resistant

 Tuberculosis in Georgia

 Jennifer Whitaker, M.D., MSc 2012

 Serial Testing for Latent Tuberculosis Infection among Healthcare Workers in the Country of Georgia

 Davit Baliashivili, M.D., MSc 2014

 Risk factors for active and latent tuberculosis (TB)

 among contacts of smear-positive index TB patients

 in the country of Georgia

 Max Adelman (MD/MSc dual degree) 2015

 Active tuberculosis case finding among Ethiopian

 Persons Living with HIV using a WHO symptom screen

 algorithm and Xpert MTB/RIF

***PhD Thesis Advisor/Thesis Committee***

 Matthew J. Magee, MPH, PhD 2013

 (Epidemiology, RSPH)

 Diabetes mellitus and active tuberculosis disease:

 Clinical presentation and treatment outcomes in adult

 tuberculosis patients: Converging Epidemics

 Jennifer K. Frediani, MS, RD, PhD 2014

 (Nutrition and Health Sciences, Graduate

 Division of Biological and Biomedical Science)

 Nutritional and Metabolic Profiling of

 Pulmonary Tuberculosis

***Medical Student***

***Summer Research Program***: MedicalStudent Summer Research 1993-2009

 Program for Tuberculosis

*B Camins; J Ahn; MP Erwin; MT Prokert;*

*EN Bisher; CE Larson; M Arrellano; M Welch;*

*B. Kinder, A Markovic, C Anderson, M. Wittkamp* (award for best poster presentation at medical student research day, 1/99)*; O. Hahn, J. Filip; M. Liao; Devon Briggs; Brian Metzger; Jason Baker, Thea Mikiashvili, Jeremy Parris, David Richards, Anand Shah, Michael Godbold, Ryan Rentz, Spencer Kozin, Olga Epstein, Katherine Shields*

***Lead Mentor for Emory Medical*** *Mark Adelman* 2010-2011

***Student Discovery Phase*** *Alexander Rabin* 2011-2012

*Karen Schmitz* 2012-2013

*Caitrin Kelly* 2014-2015

***Undergraduate Students Summer Research Projects***

*M Modansky* 1995

*D Griffin* 1996

*S Friedman* 1998

*K. Chandler* 1999

 *Angela Mosely* 2001

***Visiting Scientist:***

 *Natalia Shubladze, MS, Republic of Georgia* 1997

 *Namgyal Sherpa, M.D., India* 1998

 *Wee-Gyo Lee, M.D., Ph.D., Korea* 1999-2000

 *Natalia Shubladze, MS, Republic of Georgia* 2000, 2001

 *Ekaterina Zangaladze, PhD*, *Rep. of Georgia* 2002

 *Süheyla Serin-Senger, M.D., Turkey* 2001-2002

 *Christiane Eckhardt, M.D., Germany* 2001-2003

***Visiting Scientist:***

(*continued*) *Ekaterina Kourbatova*, *M.D., MPH, Russia* 2003-2004

 *Ulrich Seybold, M.D., MSc, Germany* 2004-2007

 *Nestani Tukvadze, M.D. Rep. of Georgia* 2007-2008

 *Medea Gegia, M.D., Republic of Georgia* 2009-2010

 *Tsira Chakhaia, M.D., Republic of Georgia*  2010

 *Giorgi Kuchukhidze, MD, MPH, Georgia* 2012

 *Davit Baliashvili, MD, Georgia* 2013-2014

 *Mariana Buziashvili, PharmD, Georgia* 2015

***INVITED LECTURES/NATIONAL***

 ***OR INTERNATIONAL CONFERENCES:***

 Southeastern Tuberculosis Controller’s Meeting

 “Atlanta TB Prevention Coalition”

 Atlanta, Georgia November 1994

 Washington, D.C. January 1995

 American Lung Association/American Thoracic Society

 An International View of Tuberculosis in New York City

 “Reaching the High Risk Patient”

 New York, New York April 7, 1995

 Republic of Georgia Public Health Conference

 “The New Tuberculosis”

 Tbilisi, Republic of Georgia August 1996

 Tuberculosis

 Emerging Infections: Clinical and Pathologic Update II

 Armed Forces Institute of Pathology, Emory University

 and CDC Atlanta, Georgia November 10, 1997

 US (NIH)-Georgia Symposium on HIV/TB and Emerging

 Infectious Diseases

 “TB: A Local and Global Perspective”

Tbilisi, Republic of Georgia May 1998

 American Association of Physician Assistants Annual

 Meeting. “Tuberculosis in the New Millennium”.

 Atlanta, GA June 1999

 Infectious Diseases Society of America Meeting

 Tuberculosis Workshop--Case Discussion: TB Treatment

 issues for drug susceptible and drug resistant strains

 Philadelphia, PA November 1999

Tuberculosis Infection Control in the 21st Century

 Sponsored by the American Thoracic Society and Infectious

 Diseases Society of America

 "One Hospital's Experience"

 "Treating latent infection in the workplace"

 Crystal City, Virginia December 1999

 American College of Physicians Annual Meeting

 Meet the Professor: "Antimicrobial Resistant Tuberculosis"

 Philadelphia, PA April 2000

***INVITED LECTURES/NATIONAL***

 ***OR INTERNATIONAL CONFERENCES:***

*(continued)*

 Infectious Diseases Society of America Meeting

 Tuberculosis Workshop--Convener/Introduction

 New Orleans, LA September 2000

 40th Interscience Conference on Antimicrobial Agents

 and Chemotherapy (ICAAC)

 "Friday Afternoon with the Hospital Epidemiologist"

 Toronto, Canada September 2000

 Georgia Division of Public Health

 Health District Directors Meeting

 "Targeted Tuberculosis Testing and Treatment of Latent

 Tuberculosis Infection"

 Stone Mountain, GA September 2000

 2001 Student National Medical Association

 Annual Conference

 Tuberculosis 2001--An Update

 Atlanta, GA April 2001

 2001 National HIV Prevention Conference

 State of the Art: The Biological, Epidemiological and

 Therapeutic Synergy of TB, STD and HIV Infection

 Atlanta, GA August 2001

 Infectious Diseases Society of America Meeting

 Tuberculosis Workshop--Convener/Introduction

 and Case Discussion: Prevention Issues: Infection Control

 and Treatment of Latent Tuberculosis Infection

 San Francisco, CA October 2001

 Focus on Fungal Infections 12

 Risk Factors for Candidal Sepsis: Recent Investigations

 Phoenix, AZ March 2002

 42nd Interscience Conference on Antimicrobial Agents

 and Chemotherapy (ICAAC)

 "Meet the Experts. Minimizing Infectious Risks to Health

 Care Workers: Needle Stick Injuries and Tuberculosis.”

 San Diego, CA: September 2002

***INVITED LECTURES/NATIONAL***

 ***OR INTERNATIONAL CONFERENCES:***

*(continued)*

 3rd National Kaiser Permanente Conference on HIV

 Mycobacterial Infections

 Atlanta, GA: October 2002

 Infectious Diseases Society of America Meeting

 Tuberculosis Workshop—Convener and Plenary

 Presentation: “New Approaches to the Treatment and

 Diagnosis of Tuberculosis”

 Chicago, IL: October 2002

 National Tuberculosis Controllers Association

 “Tuberculosis Treatment Statement”

 Washington, DC: June 2003

 Infectious Diseases Society of America Meeting

 Tuberculosis Seminar—Moderator and Speaker

 New Tuberculosis Treatment Statement”

 San Diego, CA: October 2003

 U.S.-Caucasus Grantsmanship Workshop

 Panel Discussion: mock study section/grant review

 Tbilisi, Republic of Georgia October 2003

 US (NIH)-Georgia Symposium on Biomedical

 Collaboration

 “State of the Art Lecture: Tuberculosis”

Tbilisi, Republic of Georgia October 2003

 College of Medicine Seminar

 Nosocomial Transmission of Community

 Acquired Pathogens

 University of South Alabama

 College of Medicine

 Mobile, Alabama April 2004

 6th Annual Symposium on HIV/AIDS

 Mexican Infectious Diseases Society

 HIV/TB

 Mexico City, Mexico June 2004

 Civilian Research and Development Foundation

 MDR-Tuberculosis: Epidemiologic, Diagnostic, and

 Therapeutic Research Opportunities Conference

 Emory-Georgian TB Research Collaborations

 Tbilisi, Republic of Georgia August 2004

***INVITED LECTURES/NATIONAL***

 ***OR INTERNATIONAL CONFERENCES:***

*(continued)*

 Georgia Tuberculosis Nurses Conference

 Georgia Division of Public Health

 Latent Tuberculosis Infection

 Augusta, Georgia March 2005

 Epidemiology of Tuberculosis in Georgia

 14th International Conference on AIDS, Cancer and Public

 Health.

 St. Petersburg, Russia May 2005

 National Foundation for Infectious Diseases

 2005 Annual Conference on Antimicrobial Resistance

 Control of Multi-drug Resistant Gram-Negative Bacteria in

 the Healthcare Setting

 Bethesda, Maryland June 2005

 Mycobacteriology Branch

 Division of Tuberculosis Elimination

 CDC

 Tuberculosis: a tale of two Georgias.

 Atlanta, GA September 2005

 Advisory Council on the Elimination of Tuberculosis

 Centers for Disease Control and Prevention

 How Many Sputum Smears are Necessary to Diagnose

 Pulmonary Tuberculosis?

 Atlanta, GA November 2005

MDR-TB Summit: PARTNERS for TB Control

 MDR TB Surveillance: Respondent

 Atlanta, GA May 2006

 Southeastern Center for Emerging Biological Threats

 The Challenges of Methicillin-Resistant

 *Staphylococcus aureus* as a Community Pathogen

 Clinical Syndromes associated with CA-MRSA and

 Issues for Clinical Management

 Atlanta, GA May 2006

 APIC 2006

 The Global Epidemic of Tuberculosis: Defusing the Time

 Bomb

 Tampa, FL June 2006

***INVITED LECTURES/NATIONAL***

 ***OR INTERNATIONAL CONFERENCES:***

*(continued)*

Infectious Diseases Society of America Meeting

 Tuberculosis Workshop

 Issues in the Treatment of TB 2006: Global Emergence of

 MDR and XDR-TB”

 Toronto, Canada: October 2006

KfW Regional Conference on Tuberculosis Control in the

 South Caucasus

 Capacity building for tuberculosis-related research

 Tbilisi, Georgia November 2006

TB-HIV Workshop for South

 Caucasus Countries

 Tbilisi, Republic of Georgia November 2006

 Introduction and Nosocomial Transmission of Community-

 Associated MRSA (USA300) in Healthcare Facilities

 Division of Infectious Diseases

 Medical University of South Carolina

 Charleston, SC August 2007

 National Foundation of Infectious Diseases Symposium

 MRSA: Addressing the Issues

 Hospital-Associated MRSA Infections: Is the Distinction

 Blurring?

 Chicago, IL September 2007

 San Diego, CA October 2007

 World Health Organization/Stop TB

 TB Infection Control Global Consultation

 Background and Rationale for TB Infection Control

 Geneva, Switzerland October 2007

State University of New York—Downstate

 Medical Grand Rounds

 Tuberculosis: Some Inconvenient Truths

 Brooklyn, NY December 2007

 State University of New York—Downstate

 Infectious Diseases Grand Rounds

 Nosocomial Transmission of Community-Associated

 MRSA

 Brooklyn, NY December 2007

***INVITED LECTURES/NATIONAL***

 ***OR INTERNATIONAL CONFERENCES:***

*(continued)*

 Society for Healthcare Epidemiology of America (SHEA)

 Annual Meeting

 Screening HCWs for TB Infection Using Interferon-γ

 Release Assays: Can We Make Sense of Boosting,

 Conversions and Reversions?

 Orlando, FL April 2008

 US-Georgia Workshop: The Intersections of TB, HIV,

 Hepatitis and Substance Abuse in Georgia. Setting the

 Research Agenda in Infectious Diseases

 MDR-TB: Epidemiology and Research

 Tbilisi, Georgia May 2008

Bio2008

 Antibiotic-Resistant Staphylococcal Infections:

 Challenges and Progress

 San Diego, CA June 2008

 US-Georgia Workshop

 Infectious Diseases Research Conference:

 “Implementation Science and Strengthening In-Country

 Partnerships”

 Tbilisi, Georgia May 2009

 National Tuberculosis Controllers Association

 2009 National TB Conference

 Interferon-γ Release Assay Case Studies of Implementation

 Atlanta, GA June 2009

 University of Georgia--College of Veterinary Medicine

 Department of Microbiology Seminar Series

 Utility of New (and Old) Diagnostic Tests among

 HIV-infected Persons

 Athens, GA November 2009

 5th Decennial Conference on Healthcare Associated

 Infections

 Infection Control Issues Specific to XDR-TB

 Atlanta, GA March 2010

***INVITED LECTURES/NATIONAL***

 ***OR INTERNATIONAL CONFERENCES:***

*(continued)*

 Grady Showcase

 Grady Health System

 Multidrug Resistant Organisms

 Atlanta, GA June 2010

 US-Georgia Workshop

 Infectious Disease Research Conference:

 Building Human Capacity for Research in HIV, TB,

 and Hepatitis

 Implementation Science

 Tbilisi, Georgia July 2010

 Transitioning Global Health Technologies from Labs to

 Least Developed Countries (LDCs)

 The Quest for the Holy Grail of TB Diagnostics: a Simple &

 Effective POC Test

 Rice University; Houston, TX April 2011

 Point of Care Diagnostics for Tuberculosis

 Research Seminar

 National Center for Tuberculosis and Lung Disease

 Tbilisi, Georgia June 2011

 US-Georgia Workshop/Infectious Disease Research

 Conference: Building a Regional Research Agenda

 Tuberculosis Update 2011

 Tbilisi, Georgia June 2011

 Infectious Diseases Fellowship Graduation Lecture

 Department of Medicine

 Addis Ababa University

 Tuberculosis Update 2011

 Addis Ababa, Ethiopia July 2011

 American College of Chest Physicians

 International Conference/Chest 2012

 Issues in the Management of MDR-TB& HIV co infection

 Atlanta, GA October 2012

 NIH Fogarty Emory AITRP Alumni Conference

 Update on TB and HIV Co-Infection

 Hanoi, Vietnam December 2012

***INVITED LECTURES/NATIONAL***

 ***OR INTERNATIONAL CONFERENCES:***

*(continued)*

 NIH/NIAID

 Workshop on HIV, Tuberculosis, and Hepatitis

 Global Perspective on TB/HIV

 Tbilisi, Georgia June 16-18, 2014

 National TB Controllers’ Association (NTCA)

 National TB Conference

 Continuum of TB Infection: From Exposure to Active TB

 Atlanta, GA June 8-11, 2005

***BIBLIOGRAPHY:***

***Peer Reviewed Journals***:

1. Johnson EM, **Blumberg HM**, Costrini NV, Bradshaw RA. Reduction by reserpine of the accumulation of retrogradely transported I-125-nerve growth factor in sympathetic neurons. Brain Research 1979; 178:389-401.
2. Hurwitz L, McGuffee L, Little S, **Blumberg HM**. Evidence for two distinct types of potassium activated calcium channels in an intestinal smooth muscle. J Pharm Exper Ther 1980; 214:574-80.
3. Hurwitz L, McGuffee L, Little S, **Blumberg HM**. Selective inhibition of phasic and tonic mechanical responses in potassium depolarized intestinal smooth muscle. Proc West Pharm Soc 1980; 23:459-68.
4. **Blumberg HM**, Rimland D. Nosocomial infection with penicillin-resistant pneumococci in patients with AIDS. J Infect Dis 1989; 160:725-6.
5. **Blumberg HM**, Stephens DS. Pyomyositis and human immunodeficiency virus infection. South Med J 1990; 83:1092-5.
6. Schwartz DA, Ogden PO, **Blumberg HM**, Honig E. Pulmonary malakoplakia in the acquired immunodeficiency syndrome (AIDS): differential diagnostic considerations. Arch Pathol Lab Med 1990; 114:1267-72.
7. **Blumberg HM**, Hendrix LE. Serous papillary adenocarcinoma of the tunica vaginalis of the testis with metastasis. Cancer 1991; 67:1450-3.
8. **Blumberg HM**. Oral quinolone treatment for osteomyelitis. Ann Intern Med 1991; 115:832.
9. **Blumberg HM**, Rimland D, Carroll DJ, Terry P, Wachsmuth IK. Rapid development of ciprofloxacin resistance in methicillin-susceptible and methicillin-resistant *Staphylococcus aureus*. J Infect Dis 1991; 163:1279-1285.
10. **Blumberg HM**, Kiehlbauch JA, Wachsmuth IK. Molecular epidemiology of *Yersinia enterocolitica* O:3 infections: use of DNA restriction fragment length polymorphisms of ribosomal RNA genes. J Clin Microbiol 1991; 29:2368-2374.
11. **Blumberg HM**, Rimland D, Kiehlbauch JA, Terry P, Wachsmuth IK. Epidemiologic typing of *Staphylococcus aureus* by DNA restriction fragment length polymorphisms of rRNA genes: elucidation of the clonal nature of a group of bacteriophage nontypable, ciprofloxacin-resistant, methicillin-susceptible *S*. *aureus*. J Clin Microbiol 1992;30:362-369.
12. **Blumberg HM**, Hendershot EF, Lott TJ. Persistence of the same *Candida albicans* strain despite fluconazole therapy: documentation by pulsed-field gel electrophoresis. Diag Microbiol Infect Dis 1992; 15:545-547.
13. **Blumberg HM**, Stephens DS, Licitra C, Pigott N, Facklam R, Swaminathan B, Wachsmuth IK. Molecular epidemiology of group B streptococcal infections: use of restriction endonuclease analysis of chromosomal DNA and DNA restriction fragment length polymorphisms of ribososomal RNA genes (ribotyping). J Infect Dis 1992; 166:574-579.
14. Gordon SM, **Blumberg HM**. *Mycobacterium kansasii* brain abscess in a patient with the acquired immunodeficiency syndrome. Clin Infect Dis 1992;14:789-90.
15. **Blumberg HM**. The “new tuberculosis” and its changing epidemiology. Nosocomial transmission, and hospital discharge standards. Journal of the Medical Association of Georgia 1995; 84: 209-214.
16. **Blumberg HM**, Watkins DL, Berschling JD, Antle A, Moore PP, White N, Hunter M, Green B, Ray SM, McGowan JE Jr. Preventing the nosocomial transmission of tuberculosis. Ann Intern Med 1995; 122: 658-663.
17. McGowan JE, **Blumberg HM**. Inner-city tuberculosis in the USA. J Hosp Infection 1995; 30 (supplement):282-295.
18. Zaza S, **Blumberg HM**, Beck-Sague C, Parrish C, Pineda M, Woodley C, Crawford J, McGowan J, Jarvis W. Nosocomial transmission of *Mycobacterium tuberculosis*: role of health care workers in outbreak propagation. J Infect Dis 1995; 172:1542-9.
19. Hajjeh RA, **Blumberg HM**. Bloodstream infection due to *Trichosporon beigelii* in a burn patient: case report and review of therapy. Clin Infect Dis 1995; 20:913-916.
20. **Blumberg HM**, Rimland D. Ciprofloxacin resistance among nosocomial *Pseudomonas aeruginosa* and *Staphylococcus aureus* in the United States. Infect Control Hosp Epidemiol 1995; 16:620.
21. **Blumberg HM**, Stephens DS, Modansky M, Erwin M, Elliot J, Facklam RR, Schuchat A, Baughman W, Farley MM. Invasive group B streptococcal disease: the emergence of serotype V. J Infect Dis 1996; 173:365-373.
22. **Blumberg HM**, Moore PP, Blanchard DK, Ray SM. Transmission of *Mycobacterium tuberculosis* between HIV-infected health care workers. Clin Infect Dis 1996; 22:597-8.
23. Camins BC, Bock N, Watkins DL, **Blumberg HM**. Acceptance of isoniazid therapy by health care workers after tuberculin skin test conversion. JAMA 1996; 275:1013-1015.
24. Bock NN, McGowan JE, Jr., Ahn J, Tapia J, **Blumberg HM**. Clinical predictors of tuberculosis as a guide for a respiratory isolation policy. Am J Resp Crit Care Med 1996; 154:1468-72.
25. Ray SM, Erdman D, Berschling JD, Cooper J, Torok TJ, **Blumberg HM**. Nosocomial transmission of parvovirus B19 to healthcare workers: a reassessment of risk. Infect Control Hosp Epidemiol 1997;18:109-114.
26. Zurawski CA, Case GD, Rimland D, **Blumberg HM**. Pneumonia and bacteremia in AIDS patients due to *Mycobacterium celatum* masquerading as *M. xenopi*: An underdiagnosed problem? Clin Infect Dis 1997;24: 140-3.
27. Porkert MT, Sotir M, Moore PP, **Blumberg HM**. Tuberculous meningitis at a large inner-city medical center. Am J Med Sci 1997;313:325-331.
28. **Blumberg HM**. Tuberculosis and Infection Control: What now? [editorial]. Infect Control Hosp Epidemiol 1997; 18: 538-541.
29. Bock NN, McGowan JE Jr., **Blumberg HM**. Few opportunities for tuberculosis prevention among urban poor. International Journal of Tuberculosis and Lung Disease.1998*;*2:124-129.
30. Pfaller MA, Messer SA, Houston A, Rangel-Frausto MS, Wiblin T, **Blumberg HM**, Edwards JE, Jarvis W, Martin MA, Neu HC, Saiman L, Patterson JE, Dibb JC, Roldan CM, Rinaldi MG, Wenzel RP. National epidemiology of mycoses survey: a multicenter study of strain variation and antifungal susceptibility among isolates of *Candida* species. Diag Microbiol Infect Dis 1998; 31:289-96.
31. **Blumberg HM**, Sotir M, Erwin M, Bachman R, Shulman JA. Risk of housestaff tuberculin skin test conversion in a high incidence area. Clin Infect Dis 1998; 27:826-33.
32. Bock NN, Metzger BS, Tapia JR, **Blumberg HM**. A tuberculin screening and isoniazid preventive therapy program in an inner-city population. Am J Resp Crit Care Med 1999; 159: 295-300.
33. Sotir M, Lewis C, Bisher EW, Soucie JM, **Blumberg HM**. Epidemiology of catheter-associated blood stream infections related to a long-term implantable vascular access device. Infect Control Hosp Epidemiol 1999; 20:187-191*.*
34. Bock NN, Sotir M, Parrott P, **Blumberg HM**. Nosocomial tuberculosis exposure in an outpatient setting - evaluation of patients exposed to health care providers with tuberculosis. Infect Control Hosp Epidemiol 1999; 20:421-425.
35. Rangel-Frausto MS, Wiblin T, **Blumberg HM** et al. National epidemiology of mycosis survey (NEMIS): variations in rates of *Candida* blood stream infections in seven surgical ICUs and six neonatal ICUs. Clin Infect Dis 1999; 29:253-258.
36. Marco F, Lockhart SR, Pfaller MA, Pujol C, Rangel-Frasuto MS, Wiblin T, **Blumberg HM**, Edwards JE, Jarvis W, Saiman L, Patterson JE, Rinaldi MG, Wenzel RP , the NEMIS Study Group and Soll DR. Elucidating the origins of nosocomial infections with *Candida albicans* by DNA fingerprinting with the complex probe Ca3. J Clin Microbiol 1999;37:2817-2828.
37. Reisler RB, **Blumberg HM**. Community acquired *Pseudomonas stuzeri* osteomyelitis in a previously health patient: case report and review. Clin Infect Dis 1999; 29:667-669.
38. Sotir, MJ, Parrott P, Metchock B, Bock NN, McGowan JE Jr., Ray SM, Miller LP, **Blumberg HM**. Tuberculosis in the inner city: impact of a continuing epidemic in the 1990’s. Clin Infect Dis 1999; 29:1138-1144*.*
39. Robert J, Fridkin S, **Blumberg HM**, Anderson B, White N, Ray SM, Chan J, Jarvis WR. The influence of the composition of the nursing staff on primary bloodstream infection rates in a surgical intensive care unit. Infect Control Hosp Epidemiol 2000; 21:12-17.
40. Saiman L, Ludington E, Pfaller M, Rangel-Frausto S, Wiblin RT, Dawson J, **Blumberg HM**, Patterson JE, Rinaldi M, Edwards JE, Wenzel RP, Jarvis W, and the National Epidemiology of Mycosis Survey study group. Risk factors for candidemia in Neonatal Intensive Care Unit patients. Pediatric J Infect 2000; 19:319-24.
41. **Blumberg HM**, White N, Parrott P, Gordon W, Hunter M, Ray S. False-positive tuberculin skin test results among health care workers. JAMA 2000; 283:2793.
42. Bruce BB, Blass MA, **Blumberg HM**, Lennox JL, del Rio C, Horsburgh Jr CR. Risk of *Cryptosporidium parvum* transmission between hospital roommates. Clin Infect Dis. 2000; 31:947-950.
43. Weinstock DM, Hahn O, Wittkamp M, Sepkowitz KA, Khechinashvili G, **Blumberg HM**. Risk for tuberculosis infection among internally displaced persons in the Republic of Georgia. Int J Tuberc Lung Dis 2001; 5:164-169.
44. Franco-Paredes C, **Blumberg HM**. Psoas muscle abscess caused by *Mycobacterium tuberculosis* and *Staphylococcus aureus*. Case Report and Review of the Literature. Am J Med Sci 2001; 321:415-417.
45. Franco-Paredes C, **Blumberg HM**. Latent tuberculosis infection. Consultant 2001; 41:1105-1118.
46. **Blumberg HM**, Jarvis WR, Soucie M, Edwards JE, Patterson JE, Pfaller MA, Rangel-Frausto MS, Rinaldi MG, Saiman L, Wiblin RT, Wenzel RP and the NEMIS Study Group. Risk Factors for *Candida* Bloodstream Infections in Surgical Intensive Care Units: the NEMIS Prospective Multicenter Study. Clin Infect Dis 2001; 33:177-186.
47. **Blumberg HM**, del Rio C. Management of tuberculosis. N Engl J Med 2001; 345:1501.
48. Saiman L, Ludington E, Dawson JD, Patterson JE, Rangel-Frausto S, Wiblin RT, **Blumberg HM**, Pfaller M, Rinaldi M, Edwards, JE, Wenzel RP, Jarvis W. Risk factors for *Candida* species colonization of neonatal intensive care unit patients. Pediatr Infect Dis J 2001; 20:1119-24.
49. Franco C, Leonard M, Jurado R, Smith R, **Blumberg HM**. Tuberculosis of the pancreas: report of two cases and review of the literature. Am J Med Sci 2001; 323:54-8.
50. Rezende NA, **Blumberg HM**, Metzger BS, Ray SM, McGowan JE, Jr. Risk factors for methicillin resistance among patients with *Staphylococcus aureus* bacteremia at the time of hospital admission. Am J Med Sci 2002; 323:117-23.
51. King MD, Reznik DA, O'Daniels CM, Larsen NM, Osterholt DM, **Blumberg HM**. Human papillomavirus-associated oral warts among human immunodeficiency virus-seropositive patients in the era of highly active antiretroviral therapy: an emerging infection. Clin Infect Dis 2002; 34:641-8.
52. Leonard MK, Larsen N, Drechsler H, **Blumberg H**M, Lennox JL, Arrellano M, Filip J, Horsburgh Jr CR. Increased survival of persons with tuberculosis and human immunodeficiency virus infection, 1991--2000. Clin Infect Dis 2002;34:1002-7.
53. Larsen NM, Biddle CL, Sotir MJ, White N, Parrott P, **Blumberg HM**. Risk of tuberculin skin test conversion among health care workers: occupational versus community exposure and infection. Clin Infect Dis 2002; 35:796–801.
54. Jasmer RM, Saukkonen JJ, **Blumberg HM**, Daley CL, Bernardo J, Vittinghoff E, King MD, Kawamura LM, Hopewell PC and the Short-Course Rifampin and Pyrazinamide for Tuberculosis Infection (SCRIPT) Study Investigators. Short-Course Rifampin and Pyrazinamide Compared with Isoniazid for Latent Tuberculosis Infection: A Multicenter Clinical Trial. Ann Intern Med 2002;137:640-7.
55. **Blumberg HM**, Burman WJ, Chaisson RE, et al.American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America. Treatment of Tuberculosis. Am J Respir Crit Care Med 2003; 167:603-662. [co-Chair of Writing Committee].
56. Eckhardt C, Halvosa JS, Ray SM, **Blumberg HM.** Transmission of methicillin-resistant *Staphylococcus aureus* (MRSA) in the Neonatal Intensive Care Unit from a patient with community-acquired disease. Infect Control Hosp Epidemiol 2003; 24:460-461.
57. Tobin-D'Angelo MJ, Blass MA, Del Rio C, Halvosa JS, **Blumberg HM**, Horsburgh CR. Hospital water as a source of *Mycobacterium avium* complex isolates in respiratory specimens. J Infect Dis 2004; 189:98-104.
58. Wolf J, **Blumberg HM**, Leonard MK. Laryngeal histoplasmosis. Am J Med Sci 2004;327:160-162.
59. Gira AK, Reisenauer AH, Hammock L, Nadiminti U, Macy JT, Reeves A, Burnett C, Yakrus MA, Jensent BJ, **Blumberg HM**, Caughman SW, Nolte FS. *Mycobacterium mageritense* furunculosis associated with footbaths at a nail salon. J Clin Microbiol 2004; 42:1813-7.
60. Shaukat A, Pohlel K, Rubin Z, Blumberg HM, Chow A. Case of Weil's disease in an inner-city hospital in the USA. J Gastroenterol Hepatol 2004; 19:1221-2.
61. Blumberg HM. Treatment of latent tuberculosis infection: back to the beginning. Clin Infect Dis 2004; 39:1772-5.
62. Leonard MK, Osterholt D, Kourbatova EV, del Rio C, Wang W, **Blumberg HM**. How many sputum specimens are necessary to diagnose pulmonary tuberculosis? Am J Infect Control 2005; 33:58-61.
63. **Blumberg HM**, Leonard MK Jr, Jasmer RM. Update on the treatment of tuberculosis and latent tuberculosis infection. JAMA 2005; 293:2776-2784.
64. Hidron AI, Kourbatova EV, Halvosa JS, Terrell BJ, **Blumberg HM**, King MD. Risk Factors for colonization with methicillin-resistant *Staphylococcus aureus* (MRSA) in patients admitted to an urban hospital: emergence of community-associated MRSA nasal carriage. Clin Infect Dis 2005; 41:159-66.
65. Kourbatova EV, Halvosa JS, King MD, Ray SM, White N, **Blumberg HM**. Emergence of community-associated methicillin-resistant *Staphylococcus aureus* (CA-MRSA) USA 300 clone as a cause of healthcare-associated infections among patients with prosthetic joint infections. Am J Infect Control 2005; 33:385-91.
66. [Silk BJ, del Rio C, Ivansco LK, Wetterhall SF, Augustine JJ, **Blumberg HM**, Berkelman RL.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16217979&query_hl=1) Pre-event willingness to receive smallpox vaccine among physicians and public safety personnel. South Med J 2005; 98:876-82.
67. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Controlling Tuberculosis in the United States. Am J Respir Crit Care Med 2005; 172:1169–1227. [**Blumberg HM**, co-Chair, Writing Committee]
68. [Taylor Z, Nolan CM, **Blumberg HM**; American Thoracic Society; Centers for Disease Control and Prevention; Infectious Diseases Society of America.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16267499&query_hl=1) Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. MMWR Recomm Rep. 2005; 54(RR-12):1-81
69. Leonard MK, Egan KB, Kourbatova E, White N, Parrott P, del Rio C, **Blumberg HM**. Increased efficiency in evaluating patients with suspected tuberculosis by the use of a dedicated respiratory isolation unit. Am J Infect Control 2006; 34:69-72.
70. [Whitney EA, Heilpern KL, Woods CW, Bahn CC, Franko EA, Del Rio C, Silk BJ, Ratcliff JJ, Bryant KA, Park MM, Watkins SJ, Caram LB, **Blumberg HM**, Berkelman RL.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16584326&query_hl=1&itool=pubmed_docsum) West Nile virus among hospitalized, febrile patients: a case for expanding diagnostic testing. Vector Borne Zoonotic Dis. 2006; 6:42-9.
71. Seybold U, Kourbtova EV, Johnson JG, Halvosa S, Wang WF, King MD, Ray SM, **Blumberg HM**. Emergence of community-associated methicillin-resistant *Staphylococcus aureus* (MRSA) USA300 genotype as a major cause of healthcare associated blood stream infections. Clin Infect Dis 2006; 42:647-56.
72. King MD, Terrell BJ, Wang YF, Kourbatova EV, Ray SM, **Blumberg HM**. Emergence of community-acquired methicillin-resistant *Staphylococcus aureus* USA300 clone as the predominant cause of *S. aureus* skin and soft tissue infections. Ann Intern Med 2006; 144:309-17.
73. [Leonard MK Jr, Kourbatova E, **Blumberg HM**.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16765216&query_hl=1&itool=pubmed_docsum) How many sputum specimens are necessary to diagnose pulmonary tuberculosis. Am J Infect Control 2006; 34:328-9.
74. Richards DC, Mikiashvili T, Parris JJ, Kourbatova EV, Wilson JCE, Shubladze N, Tsertvadze T, Khechinashvili G, del Rio C, **Blumberg HM**. High prevalence of hepatitis C virus infection but not HIV co-infection among patients with tuberculosis in Georgia. Int J Tuberc Lung Dis; 2006; 10:396-401.
75. **Blumberg HM**, Ray SM, King MD. Treatment of community-acquired methicillin-resistant *Staphylococcus aureus* infection. Ann Intern Med 2006; 145:232-233.
76. [Berkowitz FE, Severens JL, **Blumberg HM**.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16755481&query_hl=1&itool=pubmed_docsum) Exposure to tuberculosis among newborns in a nursery: decision analysis for initiation of prophylaxis. Infect Control Hosp Epidemiol 2006; 27:604-11.
77. [Leonard MK Jr, Kourbatova E, **Blumberg HM**.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16765216&query_hl=1&itool=pubmed_docsum) Re: how many sputum specimens are necessary to diagnose pulmonary tuberculosis. Am J Infect Control 2006; 34:328-9.
78. [Holloway KP, Rouphael NG, Wells JB, King MD, **Blumberg HM**.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17018688&query_hl=1&itool=pubmed_docsum) Polymyxin B and doxycycline use in patients with multidrug-resistant *Acinetobacter baumannii* infections in the intensive care unit. Ann Pharmacother 2006; 40:1939-45.
79. [Kourbatova EV, Borodulin BE, Borodulina EA, del Rio C, **Blumberg HM**, Leonard MK Jr.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17131780&query_hl=1&itool=pubmed_docsum) Risk factors for mortality among adult patients with newly diagnosed tuberculosis in Samara, Russia. Int J Tuberc Lung Dis 2006; 10:1224-30.
80. [Antoine TL, Curtis AB, **Blumberg HM**, Desilva K, Fransua M, Gould CV, King M, Kraman AA, Pack J, Ribner B, Seybold U, Steinberg JP, Wells JB, Sinkowitz-Cochran RL, Cardo D, Jernigan JA, Gaynes RP.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17080393&query_hl=1&itool=pubmed_docsum) Knowledge, attitudes, and behaviors regarding piperacillin-tazobactam prescribing practices: results from a multicenter study. Infect Control Hosp Epidemiol 2006; 27:1274-1277.
81. [Kourbatova EV, Leonard MK Jr, Romero J, Kraft C, Del Rio C, **Blumberg HM**.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17072539&query_hl=1&itool=pubmed_docsum) Risk factors for mortality among patients with extrapulmonary tuberculosis at an academic inner-city hospital in the US. Eur J Epidemiol 2006;21:715-21.
82. [Pai M, Kalantri S, Aggarwal AN, Menzies D, **Blumberg HM**.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17073077&query_hl=1&itool=pubmed_docsum) Nosocomial tuberculosis in India. Emerg Infect Dis 2006; 12:1311-8.
83. [Seybold U, **Blumberg HM**.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17243051&query_hl=12&itool=pubmed_docsum) Reading the tea leaves or deciphering DNA microarrays: are certain methicillin-resistant *Staphylococcus aureus* clones adapted to cause specific infections? Clin Infect Dis. 2007;44:502-5.
84. Seybold U, Talati NJ, Kizilbash Q, Shah M, **Blumberg HM**, Franco-Paredes C. Hematogenous osteomyelitis mimicking osteosarcoma due to community associated methicillin-resistant *Staphylococcus aureus.* Infection 2007; 35:190-3.
85. Seybold U, White N, Wang YF, Halvosa SJ, **Blumberg HM**. Colonization with multidrug resistant bacteria in Hurricane Katrina evacuees. Infect Control Hosp Epidemiol 2007; 28:726-729.
86. [Dukes Hamilton C, Sterling TR, **Blumberg HM**, Leonard M, McAuley J, Schlossberg D, Stout J, Huitt G.](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17599311&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum) Extensively drug-resistant tuberculosis: are we learning from history or repeating it? Clin Infect Dis. 2007; 45:338-42.
87. [Camins BC, Farley MM, Jernigan JJ, Ray SM, Steinberg JP, **Blumberg HM**.](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17620248&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum) A population-based investigation of invasive vancomycin-resistant *Enterococcus* infection in metropolitan Atlanta, Georgia, and predictors of mortality. Infect Control Hosp Epidemiol 2007;28:983-91.
88. Mirtskhulava V, Kempker R, Shields KL, Leonard MK, Tsertsvadze T, del Rio C, Salakaia A, **Blumberg HM**. Prevalence and risk factors for latent tuberculosis infection among health care workers in Georgia. Int J Tuberc Lung Dis 2008; 12:513-519
89. Seybold U, Halvosa JS, White N, Voris V, Ray SM, **Blumberg HM.** Emergence of and risk factors for methicillin-resistant *Staphylococcus aureus* of community origin in intensive care nurseries. Pediatrics 2008; 122:1039-46.
90. Mdivani N, Zangaladze E, Volkova N, Kourbatova E, Jibuti T, Shubladze N, Kutateladze T, Khechinashvili G, del Rio C, Salakaia A, **Blumberg HM**. High prevalence of multidrug-resistant tuberculosis in Georgia. Int J Infect Dis 2008; 12:635-644.
91. [Seybold U, Reichardt C, Halvosa JS, **Blumberg HM**.](http://www.ncbi.nlm.nih.gov/pubmed/18974928?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum) Clonal diversity in episodes with multiple coagulase-negative *Staphylococcus* bloodstream isolates suggesting frequent contamination. Infection. 2008; 37:256-60.
92. **Blumberg HM**. Needed: New and Better Tools to Combat Latent Tuberculosis Infection. Ann Intern Med 2008; 149:761-763.
93. Lomtadze N, Aspindzelashvili R, Janjgava M, Mirtskhulava V, Wright A, **Blumberg HM**, Salakaia A. Prevalence and Risk Factors for Multidrug-Resistant Tuberculosis in Georgia: A Population Based Study. Int J Tuberc Lung Dis 2009; 13:68-73.
94. Talati NJ, Seybold U, Humphrey B, Aina A, Tapia J, Weinfurter P, Albalak R, **Blumberg HM**. Poor concordance between interferon-γ release assays and tuberculin skin tests in diagnosis of latent tuberculosis infection among HIV-infected individuals. BMC Infectious Diseases 2009, 9:15.
95. Yamshchikov AV, Oladele A, Leonard MK Jr, **Blumberg HM**, Ziegler TR, Tangpricha V. [Vitamin D as Adjunctive Therapy in Refractory Pulmonary Tuberculosis: A Case Report.](http://www.ncbi.nlm.nih.gov/pubmed/19434014?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum) South Med J 2009; 102:649-52.
96. Jeng L, Yamshchikov AV, Judd SE, **Blumberg HM**, Martin GS, Ziegler TR, Tangpricha V. Alterations in vitamin D status and anti-microbial peptide levels in patients in the intensive care unit with sepsis. J Transl Med. 2009; 7:28.
97. Yamshchikov AV, Desai NS, **Blumberg HM**, Ziegler TR, Tangpricha V. [Vitamin D for Treatment and Prevention of Infectious Diseases: A Systematic Review of Randomized Controlled Trials.](http://www.ncbi.nlm.nih.gov/pubmed/19491064?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum) Endocr Pract 2009; 15:438-49.
98. Schaffner J, Chochua S, Kourbatova EV, Barragan M, Wang YF, **Blumberg HM**, del Rio C, Walker HK, Leonard MK. [High mortality among patients with positive blood cultures at a children's hospital in Tbilisi, Georgia.](http://www.ncbi.nlm.nih.gov/pubmed/19759489?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum) J Infect Dev Ctries. 2009;3:267-72.
99. DiazGranados CA, Jones MY, Kongphet-Tran T, White N, Shapiro M, Wang YF, Ray SM, **Blumberg HM.** [Outbreak of *Pseudomonas aeruginosa* infection associated with contamination of a flexible bronchoscope.](http://www.ncbi.nlm.nih.gov/pubmed/19379099?ordinalpos=3&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum) Infect Control Hosp Epidemiol 2009; 30:550-5.
100. Hidron AI, Low CE, Honig EG, **Blumberg HM**. Emergence of community-acquired methicillin-resistant *Staphylococcus aureus* strain USA 300 as a cause of necrotizing community-onset pneumonia. Lancet Infect Dis. 2009 Jun;9(6):384-92. doi: 10.1016/S1473-3099(09)70133-1.
101. Kobaidze K, Salakaia A, **Blumberg HM**. Over the counter availability of antituberculosis drugs in Tbilisi, Georgia in the setting of a high prevalence of MDR-TB. Interdiscip Perspect Infect Dis. 2009; 2009:513609.
102. Gaynes RP, Gould CV, Edwards J, Antoine TL, **Blumberg HM**, Desilva K, King M, Kraman A, Pack J, Ribner B, Seybold U, Steinberg J, Jernigan JA. [A multicenter study on optimizing piperacillin-tazobactam use: lessons on why interventions fail.](http://www.ncbi.nlm.nih.gov/pubmed/19530943?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum) Infect Control Hosp Epidemiol. 2009; 30:794-6.
103. Camins BC, King MD, Wells JB, Googe HL, Patel M, Kourbatova EV, **Blumberg HM**. The impact of an antimicrobial utilization program on antimicrobial use at a large teaching hospital: a randomized controlled trial. Infect Control Hosp Epidemiol 2009; 30:931-8.
104. Horsburgh CR Jr, Goldberg S, Bethel J, Chen S, Colson PW, Hirsch-Moverman Y, Hughes S, Shrestha-Kuwahara R, Sterling TR, Wall K, Weinfurter P; Tuberculosis Epidemiologic Studies Consortium. [Latent TB infection treatment acceptance and completion in the United States and Canada.](http://www.ncbi.nlm.nih.gov/pubmed/19793865) Chest. 2010;137:401-9. [HM Blumberg part of the Consortium investigators group].
105. **Blumberg HM,** Migliori GB, Ponomarenko O, Heldal E. Tuberculosis on the Move. Lancet 2010; 375:2127-2129.
106. Yamshchikov AV, Kurbatova EV, Kumari M, **Blumberg HM**, Ziegler TR, Ray SM, Tangpricha V. [Vitamin D status and antimicrobial peptide cathelicidin (LL-37) concentrations in patients with active pulmonary tuberculosis.](http://www.ncbi.nlm.nih.gov/pubmed/20610636) Am J Clin Nutr 2010; 92:603-11.
107. Magee MJ, **Blumberg HM**, Venkat Narayan K. [Commentary: Co-occurrence of tuberculosis and diabetes: new paradigm of epidemiological transition.](http://www.ncbi.nlm.nih.gov/pubmed/21252211) Int J Epidemiol 2011; 40:428-31.
108. Huskins WC, Huckabee CM, O'Grady NP, Murray P, Kopetskie H, Zimmer L, Walker ME, Sinkowitz-Cochran RL, Jernigan JA, Samore M, Wallace D, Goldmann DA; STAR\*ICU Trial Investigators. [Intervention to reduce transmission of resistant bacteria in intensive care.](http://www.ncbi.nlm.nih.gov/pubmed/21488763) N Engl J Med 2011; 364:1407-18. [HM Blumberg: member of the STAR\*ICU Trial Investigators].
109. Stephens DS, West AC, Ofili EO, Boyan BD, **Blumberg HM**. [The Atlanta Clinical and Translational Science Institute: clinical and translational science education and training partnership.](http://www.ncbi.nlm.nih.gov/pubmed/21707942) Clin Transl Sci 2011;4:143-5.
110. Weinfurter P, **Blumberg HM**, Goldbaum G, Royce R, Pang J, Tapia J, Bethel J, Mazurek G, Toney S, Albalak R. Predictors of discordant tuberculin skin test and QuantiFERON-TB In-Tube results in various high-risk groups. Int J Tuberc Lung Dis 2011; 15:1056-61.
111. Kandelaki G, Butsashvili M, Geleishvili M, Avaliani N, Macharashvili N, Topuridze M, Del Rio C, **Blumberg HM**, Tsertsvadze T. [Nosocomial infections in Tbilisi, Georgia: a retrospective study of microbiological data from 4 major tertiary care hospitals.](http://www.ncbi.nlm.nih.gov/pubmed/21828982) Infect Control Hosp Epidemiol 2011; 32:933-4.
112. Nair N, Kourbatova E, Poole K, Huckabee CM, Murray P, Huskins C, **Blumberg HM**. Molecular Epidemiology of methicillin-resistant *Staphylococcus aureus* (MRSA) among patients admitted to adult Intensive Care Units: the STAR\*ICU Trial. Infect Control Hosp Epidemiol; 2011; 32:1057-63.
113. Talati N, Gonzalez-Diaz E, Mutemba C, Wendt J, Kilembe W, Mwananyanda L, Chomba E, Allen S, del Rio C, **Blumberg HM**. Diagnosis of latent tuberculosis infection among HIV discordant partners using interferon-γ release assays. BMC Infect Dis 2011;11:264.
114. Desai NS, Tukvadze N, Frediani JK, Kipiani M, Sanikidze E, Nichols MM, Hebbar G, Kempker RR, Mirtskhulava V, Kalandadze I, Seydafkan S, Sutaria N, Chen TC, **Blumberg HM**, Ziegler TR, Tangpricha V. [Effects of sunlight and diet on vitamin D status of pulmonary tuberculosis patients in Tbilisi, Georgia.](http://www.ncbi.nlm.nih.gov/pubmed/22304856) Nutrition 2012; 28:362-6.
115. Kempker RR, Rabin AS, Nikolaishvili K, Kalandadze I, Gogishvili S, **Blumberg HM**, Vashakidze S. Additional drug resistance in *Mycobacterium tuberculosis* isolates from resected cavities among pulmonary M/XDR-TB patients. Clin Infect Dis 2012; 54(6):e51-4.
116. Tukvadze N\*, Kempker RR**\***, Kalandadze I, Kurbatova E, Leonard MK, **Blumberg HM**. Use of a molecular diagnostic test in AFB smear positive tuberculosis suspects greatly reduces time to detection of multidrug resistant tuberculosis. PLoS One 2012;7(2):e31563*.*
117. Kempker RR, Vashakidze S, Solomonia N, Dzidzikashvili N, **Blumberg HM**. Surgery in drug-resistant tuberculosis. Lancet Infect Dis 2012;12:157-66*.*
118. Leeds IL, Magee MJ, Kurbatova EV, Del Rio C, **Blumberg HM**, Leonard MK, Kraft CS. [Site of Extrapulmonary Tuberculosis is Associated with HIV Infection.](http://www.ncbi.nlm.nih.gov/pubmed/22423123) Clin Infect Dis 2012; 55:75-81.
119. Gegia M, Kalandadze I, Kempker RR, Magee MJ, **Blumberg HM.** Adjunctive surgery improves treatment outcomes among patients with multidrug-resistant and extensively drug-resistanttuberculosis. Int J Infect Dis 2012; 16(5):e391-6.
120. Magee MJ, **Blumberg HM**, Broz D, Furner SE, Samson L, Singh S, Hershow RC. [Prevalence of drug resistant tuberculosis among patients at high-risk for HIV attending outpatient clinics in Delhi, India.](http://www.ncbi.nlm.nih.gov/pubmed/23082587) Southeast Asian J Trop Med Public Health 2012; 43:354-63.
121. Zhao VM, Griffith DP, **Blumberg HM**, Dave NJ, Battey CH, McNally TA, Easley KA, Galloway JR, Ziegler TR. [Characterization of post-hospital infections in adults requiring home parenteral nutrition.](http://www.ncbi.nlm.nih.gov/pubmed/22858199) Nutrition 2013; 29:52-9.
122. Alemu AS, Kempker RR, Tenna A, Smitson C, Berhe N, Fekade D, **Blumberg HM**, Aseffa A. High Prevalence of Cryptococcal Antigenemia among HIV-infected Patients Receiving Antiretroviral Therapy in Ethiopia. PLoS One 2013; 8(3):e58377.
123. Rabin AS, Kuchukhidze G, Sanikidze E, Kempker RR, **Blumberg HM**. Prescribed and self-medication use increase delays in diagnosis of tuberculosis in the country of Georgia. Int J Tuberc Lung Dis 2013; 17:214-20.
124. Whitaker J, Mirtskhulava V, Kipiani M, Harris DA, Tabagari N, Kempker RR, **Blumberg HM**. Prevalence and incidence of latent tuberculosis infection in Georgian healthcare workers. PLoS ONE 2013; 8(3):e58202.
125. Vashakidze S, Gogishvili S, Nikolaishvili K, Dzidzikashvili N, Tukvadze N, **Blumberg HM**, Kempker RR. Favorable Outcomes for Patients with Multidrug- and Extensively Drug Resistant Tuberculosis Patients Undergoing Adjunctive Surgery. Ann Thoracic Surg 2013; 95:1892-8.
126. Marks SM, Cronin W, Venkatappa T, Maltas G, Chon S, Sharnprapai S, Gaeddert M, Tapia J, Dorman SE, Etkind S, Crosby C, **Blumberg HM**, Bernardo J. The Health-System Benefits and Cost-effectiveness of Using *Mycobacterium tuberculosis* Direct Nucleic Acid Amplification Testing to Diagnose Tuberculosis Disease in the United States. Clin Infect Dis 2013; 57:532-42.
127. Frediani JK, Tukvadze N, Sanikidze E, Kipiani M, Hebbar G, Easley KA, Shenvi N, Ramakrishnan U, Tangpricha V, **Blumberg HM**, Ziegler TR. [A culture-specific nutrient intake assessment instrument in patients with pulmonary tuberculosis.](http://www.ncbi.nlm.nih.gov/pubmed/23541173) Clin Nutr 2013; 32:1023-8.
128. Zaeh S, Kempker R, Stenehjem E, **Blumberg HM**, Temesgen O, Ofotokun I, Tenna A. [Improving tuberculosis screening and isoniazid preventive therapy in an HIV clinic in Addis Ababa, Ethiopia.](http://www.ncbi.nlm.nih.gov/pubmed/24125440) Int J Tuberc Lung Dis. 2013;17(11):1396-401. doi: 10.5588/ijtld.13.0315.
129. Tenna A, Stenehjem EA, Margoles L, Kacha E, **Blumberg HM**, Kempker RR. [Infection control knowledge, attitudes, and practices among healthcare workers in Addis Ababa, Ethiopia.](http://www.ncbi.nlm.nih.gov/pubmed/24225614) Infect Control Hosp Epidemiol 2013; 34:1289-96.
130. Chkhartishvili N, Kempker RR, Dvali N, Abashidze L, Sharavdze L, Gabunia P, **Blumberg HM**, Del Rio C, Tsertsvadze T. [Poor agreement between interferon-gamma release assays and the tuberculin skin test among HIV-infected individuals in the country of Georgia.](http://www.ncbi.nlm.nih.gov/pubmed/24176032) BMC Infect Dis 2013; 13:513. doi: 10.1186/1471-2334-13-513.
131. Lomtadze N, Kupreishvili L, Salakaia A, Vashakidze S, Sharvadze L, Kempker RR, Magee MJ, del Rio C, **Blumberg HM**. [Hepatitis C virus co-infection increases the risk of anti-tuberculosis drug-induced hepatotoxicity among patients with pulmonary tuberculosis.](http://www.ncbi.nlm.nih.gov/pubmed/24367617) PLoS ONE 2013; 8(12):e83892. doi: 10.1371/journal.pone.0083892.
132. Smitson CC, Tenna A, Tsegaye M, Alemu AS, Fekade D, Aseffa A, **Blumberg HM**, Kempker RR. No association of cryptococcal antigenemia with poor outcomes among antiretroviral therapy-experienced HIV-infected patients in Addis Ababa, Ethiopia. PloS ONE 2014;9:e85698.
133. Magee MJ, Foote M, Maggio DM, Howards PP, Narayan KM, **Blumberg HM**, Ray SM, Kempker RR. [Diabetes mellitus and risk of all-cause mortality among patients with tuberculosis in the state of Georgia, 2009-2012.](http://www.ncbi.nlm.nih.gov/pubmed/24613196) Ann Epidemiol 2014; 24:369-75.
134. Tukvadze N, Bablishvili N, Apsindzelashvili R, **Blumberg HM**, Kempker RR. [Performance of the MTBDRsl assay in Georgia.](http://www.ncbi.nlm.nih.gov/pubmed/24429319) Int J Tuberc Lung Dis. 2014;18:233-9.
135. Magee MJ, Kempker RR, Kipiani M, Tukvadze N, Howards PP, Narayan KM, **Blumberg HM**. Diabetes mellitus, smoking status, and rate of sputum culture conversion in patients with multidrug-resistant tuberculosis: a cohort study from the country of Georgia. PLoS ONE 2014; 9:e94890.
136. Schmitz K, Kempker RR, Tenna A, Stenehjem E, Abebe E, Tadesse L, Jirru EK, **Blumberg HM**. [Effectiveness of a multimodal hand hygiene campaign and obstacles to success in Addis Ababa, Ethiopia.](http://www.ncbi.nlm.nih.gov/pubmed/24636693) Antimicrob Resist Infect Control 2014;3(1):8. doi: 10.1186/2047-2994-3-8.
137. Adelman MW, Kurbatova E, Wang YF, Leonard MK, White N, McFarland DA, **Blumberg HM**. Cost Analysis of a Nucleic Acid Amplification Test in the Diagnosis of Pulmonary Tuberculosis at an Urban Hospital with a High Prevalence of TB/HIV. PloS one 2014; 9:e100649.
138. Kipiani M, Mirtskhulava V, Tukvadze N, Magee M, **Blumberg HM**, Kempker RR. Significant Clinical Impact of a Rapid Molecular Diagnostic Test (Genotype MTBDRplus Assay) to detect Multidrug-Resistant Tuberculosis. Clin Infect Dis 2014; 59:1559-66. doi: 10.1093/cid/ciu631
139. **Blumberg HM**, Kempker RR. Interferon-Gamma Release Assays for the Evaluation of Latent Tuberculosis Infection. JAMA 2014; 312:1460-1*.*
140. Frediani JK, Jones DP, Tukvadze N, Uppal K, Sanikidze E, Kipiani M, Tran VT, Hebbar G, Walker DI, Kempker RR, Kurani SS, Colas RA, Dalli J, Tangpricha V, Serhan CN, **Blumberg HM**, Ziegler TR. Plasma metabolomics in human pulmonary tuberculosis disease: a pilot study. PLoS One 2014; 9(10):e108854. doi: 10.1371/journal.pone.0108854.
141. Kuchukhidze, G, Kumar AM, de Colombani P, Khogali M, Nanava U, **Blumberg HM**, Kempker RR. Risk factors associated with loss to follow-up among multidrug-resistant tuberculosis patients in Georgia. Public Health Action 2014; 4 (Supplement 2): S41-S46.
142. Chakhaia T, Magee MJ, Kempker RR, Gegia M, Goginashvili L, Nanava U, **Blumberg HM**. High utility of contact investigation for latent and active tuberculosis case detection among contacts: a retrospective cohort study in Tbilisi, Georgia, 2010-2011. PLoS One. 2014; 9(11):e111773. doi: 10.1371/journal.pone.0111773.
143. Hirsch-Moverman Y, Shrestha-Kuwahara R, Bethel J, **Blumberg HM**, Venkatappa TK, Horsburgh CR, Colson PW; Tuberculosis Epidemiologic Studies Consortium (TBESC). [Latent tuberculous infection in the United States and Canada: who completes treatment and why?](http://www.ncbi.nlm.nih.gov/pubmed/25519787) Int J Tuberc Lung Dis. 2015; 19:31-8. doi: 10.5588/ijtld.14.0373.
144. Mirtskhulava V, Whitaker JA, Kipiani M, Harris DA, Tabagari N, Owen-Smith AA, Kempker RR, **Blumberg HM**. Determinants of tuberculosis infection control-related behaviors among healthcare workers in the country of Georgia. Infect Control Hosp Epidemiol 2015; 36:522-8.
145. Magee MJ, Kempker RR, Kipiani M, Gandhi NR, Darchia L, Tukvadze N, Howards PP, Narayan KM, **Blumberg HM**. Diabetes mellitus is associated with cavities, smear grade, and multidrug resistant tuberculosis in Georgia. Int J Tuberc Lung Dis 2015; 19:685-92.
146. Kempker RR, Kipiani M, Mirtskhulava V, Tukvadze N, Magee MJ, **Blumberg HM**.Acquired Drug Resistance and Association with Poor Outcomes among Patients with Multidrug-Resistant Tuberculosis. Emerg Infect Dis 2015; 21:992-1001.

1. Bablishvili N, Tukvadze N, Avaliani Z, **Blumberg HM**, Kempker RR. A comparison of the Xpert(®) MTB/RIF and GenoType(®) MTBDRplus assays in Georgia. Int J Tuberc Lung Dis. 2015; 19:676-8.
2. Frediani JK, Sanikidze E, Kipiani M, Tukvadze N, Hebbar G, Ramakrishnan U, Jones DP, Easley KA, Shenvi N, Kempker RR, **Blumberg HM**, Tangpricha V, Ziegler TR. Macronutrient intake and body composition changes during anti-tuberculosis therapy in adults. Clin Nutrition 2015 [epub Feb 26]; *in press.*
3. Heeke AL, **Blumberg HM**, Perry JM, Weiss DS, Crispell EK, Satola SW, Salinas JL. A case of disseminated emm Type 12 Group A Streptococcus and Review of Invasive Disease. Am J Med Sci 2015 [epub Feb 26]; *in press.*
4. Medea G, Magee MJ, Chakhaia T, Kempker RR, Kalandadze I, Golub J, **Blumberg HM**. Smoking increases the risk of poor tuberculosis treatment outcomes: a cohort study from the country of Georgia. BullWorld Health Organ 2015; 93:390–399.
5. Kempker RR, Barth AB, Vashakidze S, Nikolaishvili K, Sabula I, Tukvadze N, Bablishvili N, Gogishvili S, Shankar R, Singh P, Guarner, J, Derendorf H, Peloquin, CA, **Blumberg HM**. Cavitary Penetration of Levofloxacin among Patients with Multidrug-Resistant Tuberculosis . Antimicrob Agents Chemother 2015; 59:3149-55.
6. Hensel RL, Kempker RR, Tapia J, Oladele A, **Blumberg HM**, Magee MJ. Increased risk of latent tuberculosis infection among persons with pre-diabetes and diabetes mellitus. Int J Tuberc Lung Dis 2015; *in press*.
7. Adelman MW\*, Tsegaye M\*, Kempker RR, Alebachew T, Haile K Tesfaye A, Aseffa A, **Blumberg HM**. Intensified tuberculosis case finding among HIV-infected persons using a WHO symptom screen and Xpert MTB/RIF. Int J Tuberc Lung Dis 2015; *in press*.

**Textbook Chapters:**

Kozarsky P, Blumberg HM. The acquired immunodeficiency syndrome, In: Morse SA, Moreland AA, Thompson SE III (eds): Atlas of Sexually Transmitted Diseases. New York: Gower Medical Publishing Co., 1989.

Shulman JA, Blumberg HM. Spinal and paraspinal infections, In: Lambert HP (ed). Central nervous system infections, In: Kass E, Weller T, Wolff S, Tyrell D. Handbook of Infectious Diseases. Philadelphia: B.C. Decker, Inc., 1991, pp 374-391.

Blumberg HM. Staphylococcal infections, In: Hurst JW (ed): Medicine for the Practicing Physician. 3rd Edition. Boston: Butterworths, 1992, pp 377-381.

Blumberg HM, Shulman JA, Prokesch R. Strongyloidiasis, In: Hurst JW (ed): Medicine for the Practicing Physician. 3rd Edition. Boston: Butterworths, 1992, pp 429-431.

Blumberg HM. Staphylococcal infections, In: Hurst JW (ed): Medicine for the Practicing Physician. 4th Edition. Norwalk, CT: Appleton and Lange, 1996, pp.402-6.

Blumberg HM, Shulman JA. Strongyloidiasis, In: Hurst JW (ed): Medicine for the Practicing Physician. 4th Edition. Norwalk, CT: Appleton and Lange, 1996, pp. 462-4.

Blumberg HM, Nelson AM. Tuberculosis. In: Nelson, AM, Horsburgh, CR, eds. Pathology of Emerging Infections, Volume II, Washington, DC: ASM Press, 1998, pp167-192.

Blumberg HM. Tuberculosis Infection Control., In: Reichman LB, Hershield E, eds. Tuberculosis: A Comprehensive International Approach. 2nd Edition. New York: Marcel-Dekker, Inc., 2000, pp 609-644.

Shulman JA, Blumberg HM. Anthrax., In: Goldman L, Ausiello D, eds. Cecil Textbook of Medicine, 22nd edition. Philadelphia, PA: W.B. Saunders, 2004, 1870-1875.

Blumberg HM. Tuberculosis Infection Control in Healthcare Settings. In: Lautenbach E, Woeltje K, eds. Practical Handbook for Healthcare Epidemiologists, 2nd edition. Thorofare, NJ: Slack Inc., 2004.

Blumberg HM. Antimycobacterial Agents. In: Minneman K, ed. Brody’s Human Pharmacology, 4th edition. Philadelphia, PA: Elsevier, 2006.

Leonard MK, Blumberg, HM. Musculoskeletal Tuberculosis. In: Schlossberg DA, ed. Tuberculosis, 5th edition. New York, NY: McGraw-Hill Inc., 2006*.*

Blumberg HM, Leonard MK. Tuberculosis. In: Dale DC, ed. ACP Medicine. New York, N.Y.: WebMD Professional Publishing, 2006.

Leonard MK, Blumberg HM. Non-tuberculosis Mycobacteria. In: Dale DC, ed. ACP Medicine. New York, N.Y.: WebMD Professional Publishing, 2006.

Blumberg HM. Tuberculosis Infection Control in Healthcare Settings. In: Lautenbach E, Woeltje K, Malani PN, eds. Practical Healthcare Epidemiology, 3rd edition. Chicago, IL: University of Chicago Press, 2010.

Leonard MK, Franco-Paredes C, Blumberg HM. Non-tuberculosis Mycobacteria. In: Nabel EG, ed. ACP Medicine. New York, N.Y.: BC Decker Inc, 2011.

Leonard MK, Blumberg HM. Musculoskeletal Tuberculosis. In: Schlossberg DA, ed. Tuberculosis, 6th edition. New York, NY: McGraw-Hill Inc., 2011*.*

Parr J, Leonard MK, Blumberg HM. Tuberculosis. In: Nabel EG, ed. ACP Medicine. New York, N.Y.: BC Decker Inc, 2013.

Blumberg, HM, Talati, N. Tuberculosis Infection Control in Clinical Decision Support: Hospital Infection Control, edited by Wenzel, RW and Bearman, G. 2014. Decision Support in Medicine, LLC. Wilmington, DE

***Other Publications***:

Blumberg HM, Bock NN, eds. Georgia TB Reference Guide, July 1995.

Blumberg HM, Bock NN, eds. Georgia TB Reference Guide, July 1996.

Blumberg HM, Bock NN, eds. Georgia TB Reference Guide, July 1997.

Blumberg HM, Bock NN, eds. Georgia TB Reference Guide, July 1998.

Blumberg HM, Bock NN, eds. Georgia TB Reference Guide, July 1999.

Blumberg HM, Bock NN, eds. Georgia TB Reference Guide, July 2000.

Blumberg HM, Bock NN, eds. Georgia TB Reference Guide, September 2001.

Blumberg HM, Leonard MK Jr, eds. Georgia TB Reference Guide, January 2005.

Blumberg HM, Ray SM, eds. Georgia TB Reference Guide, 2014.

Institute of Medicine (IOM) Committee on Regulating Occupational Exposure to Tuberculosis. Field MJ, Editor. Tuberculosis in the Workplace. National Academy Press: Washington, D.C., 2001. [member of committee]